{
    "ticker": "CRIS",
    "name": "Curis, Inc.",
    "description": "Curis, Inc. is a biotechnology company focused on the development of innovative drug candidates for the treatment of cancer. Founded in 2000 and headquartered in Lexington, Massachusetts, Curis is dedicated to advancing the field of targeted therapies and immuno-oncology. The company's lead product candidate, CUDC-907, is an orally available dual inhibitor of histone deacetylases (HDAC) and phosphoinositide 3-kinase (PI3K), designed to treat various forms of cancer. Curis also has a strategic partnership with Genentech, a member of the Roche Group, to develop and commercialize a range of cancer therapies. The company leverages cutting-edge research in molecular biology and genetics to discover and develop novel therapeutic approaches that can improve patient outcomes. With a mission to transform the treatment landscape for cancer patients, Curis is committed to bringing forth new hope through scientific excellence and dedication to patient care. As the industry evolves, Curis continues to explore new avenues for collaboration and innovation, aiming to address unmet medical needs in oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2000",
    "website": "https://www.curis.com",
    "ceo": "James Dentzer",
    "social_media": {
        "twitter": "https://twitter.com/CurisInc",
        "linkedin": "https://www.linkedin.com/company/curis-inc"
    },
    "investor_relations": "https://investors.curis.com",
    "key_executives": [
        {
            "name": "James Dentzer",
            "position": "CEO"
        },
        {
            "name": "Michael S. R. M. Martino",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drug Candidates",
            "products": [
                "CUDC-907"
            ]
        }
    ],
    "seo": {
        "meta_title": "Curis, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Curis, Inc., a biotechnology firm dedicated to developing innovative therapies for cancer treatment. Discover their product pipeline and commitment to patient care.",
        "keywords": [
            "Curis",
            "Biotechnology",
            "Cancer Treatment",
            "Oncology",
            "CUDC-907"
        ]
    },
    "faq": [
        {
            "question": "What is Curis known for?",
            "answer": "Curis is known for developing innovative drug candidates for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Curis?",
            "answer": "James Dentzer is the CEO of Curis, Inc."
        },
        {
            "question": "Where is Curis headquartered?",
            "answer": "Curis is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What is Curis's lead product candidate?",
            "answer": "Curis's lead product candidate is CUDC-907."
        },
        {
            "question": "When was Curis founded?",
            "answer": "Curis was founded in 2000."
        }
    ],
    "competitors": [
        "CLVS",
        "BMY",
        "EXEL",
        "INCY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}